Join ASTHO and CDC to learn about opportunities to assess, prepare, and implement programs that prevent the spread of HIV, viral hepatitis, and other infectious diseases related to the opioid epidemic. Expert panelists will discuss evidence-based practices that reduce the harmful health outcomes associated with injection drug use and link clients to treatment programs.
State and local representatives from Vermont will share their perspectives on policy levers and activities needed at the community level to implement syringe services programs (SSPs). Representatives will share lessons learned related to developing and implementing SSPs and building linkages to treatment for substance misuse.
- Alice K. Asher, Epidemiologist, Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC
- Daniel J. Daltry, Program Chief, HIV/ STD/ Hepatitis Program, Vermont Department of Health
- Grace Keller, Program Coordinator, Howard Center Safe Recovery
By the end of the webinar, participants will be able to:
- Describe the infectious disease consequences of the opioid epidemic, including HIV, hepatitis C, rising MRSA infections, endocarditis, and hepatitis A.
- Find resources and evidence-based tools that help them understand their state’s vulnerability to the infectious disease consequences of the opioid crisis.
- Explain SSPs and how these programs benefit clients, communities, and public health and healthcare systems.
- Apply what they learn about how Vermont is using policies and partnerships to reduce the harmful consequences of opioid use.